stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Free cash flow margin
Royalty Pharma PLC's free cash flow margin over the twelve months to 30 September 2026 was 113.1%, up 8.4 percentage points from fiscal 2025 (104.7%). Over the past ten years it has ranged from −7.60% (fiscal 2021) to 126.9% (fiscal 2023); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 104.7% | (16.84) |
| FY2024 | 121.5% | (5.36) |
| FY2023 | 126.9% | 32.01 |
| FY2022 | 94.9% | 102.48 |
| FY2021 | −7.60% | (0.64) |
| FY2020 | −6.96% | (3.98) |
| FY2019 | −2.98% | (78.12) |
| FY2018 | 75.1% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| RPRX Royalty Pharma PLC | 113.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 21.9% |
| INCY Incyte Corporation compare | 11.3% |
| ARGX argenex SE compare | 0.00% |
| BNTX BioNTech SE Sponsored ADR compare | −19.2% |
| INSM Insmed, Inc. compare | −41.3% |
| GMAB Genmab A/S Sponsored ADR compare | −153.6% |
| RVMD Revolution Medicines, Inc. compare | −688.9% |
| ROIV Roivant Sciences Ltd. compare | −10,901.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement